



18 October 2016

Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

**COMPANY ANNOUNCEMENTS - RESULTS OF THE 2016 ANNUAL GENERAL MEETING**

In accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001, I advise that the shareholders of OncoSil Medical Ltd (ASX:OSL) passed all resolutions considered at the Annual General Meeting of shareholders held today, namely:

Resolution 1 – Adoption of Remuneration Report

Resolution 2 – Re-election of Roger Aston

Resolution 3 – Ratification of Issue of Shares to Regal Funds Management

All resolutions were passed unanimously on a show of hands. It was noted for the record that the show of hands and proxy position in relation to the resolutions were well in excess of the required majorities for the passing of the resolutions.

The proxy votes for the resolutions were as follows:

Resolution	For	Against	Abstain
Resolution 1 - Adoption of Remuneration Report	83,894,059	1,727,194	1,174,632
Resolution 2 - Re-election of Roger Aston	111,577,827	224,354	2,600,759
Resolution 3 - Ratification of issue of shares to Regal Funds Management	110,968,541	1,168,011	2,840,045

Kind regards  
OncoSil Medical Ltd

A blue ink signature of Tom Milicevic, consisting of a stylized 'T' and 'M'.

**Tom Milicevic**  
Company Secretary

## About OncoSil Medical Ltd

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian Lifesciences company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic cancer. FDA and CE Mark approval for pancreatic cancer is the core focus of OncoSil Medical.

## Pancreatic Cancer

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

## Hepatocellular carcinoma liver cancer

Hepatocellular carcinoma (HCC) is the 6<sup>th</sup> most common cancer in the world with 782,000 new cases diagnosed in 2012. It's very poor prognosis makes HCC the third leading cause of cancer related mortality responsible for approximately 600,000 deaths annually. Hepatocellular carcinoma can be cured by surgery or transplantation. The vast majority of patients with HCC have disease which is too advanced for surgical intervention and as a consequence survival ranges from a few months to two or more years depending on the liver function at diagnosis and the extent of tumour invasion. The value of the hepatocellular cancer (HCC) market is expected to triple in size to \$1.4b by 2019.

## References

- Global Industry Analysts 2010
- BIOSDP-201. A single dose, single centre open label Phase I/II Safety Study in Hepatocarcinoma
- Venook et al. The incidence of Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The Oncologist; 15 Supplement 5-13
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/pancreatic-cancer-statistics>
- <http://www.datamonitorhealthcare.com/hepatocellular-cancer-market-to-treble-in-size-by-2019>
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/liver-cancer-statistics>